FDA Warning Letter To Cordis: Controls Lacking To Ensure Stent Quality
This article was originally published in The Gray Sheet
Johnson & Johnson/Cordis released units of its Cypher drug-eluting stent to the market even though stents in some lots were shown by internal company testing not to expand completely, according to an FDA warning letter.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.